These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7868336)

  • 21. A cost-effective approach to managing infectious disease.
    Wright RA
    Consultant; 1989 May; 29(5):143-6, 150, 155. PubMed ID: 10292917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ambulatory payment classifications: information technology to the rescue.
    Kiel JM
    MD Comput; 2000; 17(5):17-8. PubMed ID: 11050853
    [No Abstract]   [Full Text] [Related]  

  • 23. Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine.
    Charles JA; von Dohln P
    Headache; 2010 May; 50(5):852-60. PubMed ID: 20132337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches.
    Klapper JA; Stanton J
    Headache; 1992 Jan; 32(1):21-3. PubMed ID: 1372884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
    Payne K; Kozma CM; Lawrence BJ
    Pharmacoeconomics; 1996 Jul; 10(1):59-71. PubMed ID: 10160470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine.
    Baumgartner A; Jacot N; Moser G; Krähenbühl B
    Vasa; 1989; 18(2):152-6. PubMed ID: 2545054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous dihydroergotamine to relieve pelvic congestion with pain in young women.
    Reginald PW; Beard RW; Kooner JS; Mathias CJ; Samarage SU; Sutherland IA; Wadsworth J
    Lancet; 1987 Aug; 2(8555):351-3. PubMed ID: 2886820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intranasally-administered dihydroergotamine in the rat.
    Lau DT; Yu Z; Aun RL; Hassell AE; Tse FL
    Pharm Res; 1994 Nov; 11(11):1530-4. PubMed ID: 7870666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost of asthma.
    Bus Health; 1995 Jul; 13(7 Suppl D):6-9. PubMed ID: 10144996
    [No Abstract]   [Full Text] [Related]  

  • 33. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure.
    Buckley LF; Seoane-Vazquez E; Cheng JW; Aldemerdash A; Cooper IM; Matta L; Medina DS; Mehra MR; Navarro-Velez K; Shea EL; Weintraub JR; Stevenson LW; Desai AS
    Am J Cardiol; 2016 Nov; 118(9):1350-1355. PubMed ID: 27772698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repetitive intravenous DHE in the treatment of refractory headache.
    Silberstein SD; Schulman EA; Hopkins MM
    Headache; 1990 May; 30(6):334-9. PubMed ID: 2370132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.
    Wyss PA; Rosenthaler J; Nüesch E; Aellig WH
    Eur J Clin Pharmacol; 1991; 41(6):597-602. PubMed ID: 1815973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of oral dihydroergotamine in the management of vascular disorders.
    Rumboldt Z; Bagatin J; Sardelić S
    Clin Pharmacol Ther; 1995 Aug; 58(2):237-8. PubMed ID: 7648774
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
    Kellerman D; Kori S; Forst A; Chang J; Febbraro S; Wutann L; Thomas T; Taylor G; Dodick D
    Cephalalgia; 2012 Jan; 32(2):150-8. PubMed ID: 22174351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health reform. Discount drug program could save eligible hospitals millions of dollars.
    Ament L
    Hosp Health Netw; 2010 Jul; 84(7):9. PubMed ID: 20698336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.